-
A Treatment That Came Just in Time
Cancer survivor Laurie Adami reflects on her experience participating in a clinical trial that ultimately contributed to the March 2021 approval of a CAR-T cell therapy for follicular lymphoma.
by Laurie Adami
-
Expanding Immunotherapy
At a patient advocate event, researchers discussed how to extend the benefits of immunotherapy to more people.
by Kevin McLaughlin
-
How Long Do Immunotherapy Side Effects Last?
For people with melanoma who receive immune checkpoint inhibitors after surgery, side effects can remain even after treatment has been completed. These chronic side effects are most often mild.
by Anna Goshua
-
Immunotherapy Indications Withdrawn
In recent months, drugmakers have announced they are withdrawing indications for four immune checkpoint inhibitors in consultation with the Food and Drug Administration. What does this mean for patients who are taking these drugs?
by Anna Goshua
-
Patient Advocates Tune in for Precision Medicine Primer
Scientists and physicians discussed advances in targeted therapies and immunotherapies, as well as the lessons COVID-19 research has taught to cancer researchers.
by Kevin McLaughlin
-
Immunotherapy Options for Breast Cancer
Two immune checkpoint inhibitors are now approved for treatment of some people with advanced breast cancer, but trial results have raised some questions.
by Anna Goshua
-
What Is Tumor Mutational Burden?
The Food and Drug Administration approved an immunotherapy drug for tumors with high tumor mutational burden regardless of tumor type. But some medical oncologists say it's not clear the biomarker is valid across all cancer types.
by Anna Azvolinsky
-
Treating Cancer Patients With COVID-19: A New York City Experience
An analysis of cancer patients who were infected with the coronavirus and treated at Memorial Sloan Kettering Cancer Center in New York City suggests certain risk factors may predict more severe COVID-19.
by Anna Azvolinsky
-
Exploring Immunotherapy for Triple Negative Breast Cancer
Following the approval of the first immunotherapy for breast cancer by the U.S. Food and Drug Administration in March 2019, experts at the San Antonio Breast Cancer Symposium discussed avenues for further development.
by Marci A. Landsmann
-
Navigating Hospital Discharge Decisions
Patients with advanced cancer often go to rehabilitation facilities after a hospital stay in hopes of gaining the strength for further treatment, but the majority do not go on to receive additional cancer therapy, a study reports.
by Ashley P. Taylor
Cancer Talk
Support groups offer community for people with cancer in a world that doesn’t understand their experience.
by Carly Flumer
Making Informed Consent AccessibleConfusing informed consent forms are a common barrier to clinical trial participation. Researchers ask how they can be better designed for patients.
by Sandra Gordon
Keep That Colonoscopy AppointmentExperts weigh in on a recent study appearing to show that colonoscopy had lower-than-expected efficacy for preventing colorectal cancer.
by Pamela Rafalow Grossman
What We Know About Ultraprocessed Foods and Cancer RiskResearch has linked highly processed foods like deli meat to a higher risk of colorectal cancer in men.
by Jon Kelvey
From the AACR
-
AACR Cancer Progress Report
The vital importance of research for improving health and saving lives from cancer is highlighted in this twelfth edition of the annual American Association for Cancer Research (AACR) Cancer Progress Report.
-
How Our Senses Affect Cancer Development
Dr. Patricia LoRusso’s parents both died of cancer when she was a teenager, inspiring her to become an oncologist and focus on developing new treatments for people with cancer.
Video
Drugging the Elusive KRAS
